Form 4: Theravance Biopharma Executive Sells Shares to Cover Tax Obligations

A Theravance Biopharma executive, Rhonda Farnum, sold 9,178 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Rhonda Farnum, a Senior Vice President at Theravance Biopharma, sold 9,178 ordinary shares on November 20, 2024.
• The shares were sold at a price of $9.97 per share.
• This transaction was to cover tax obligations arising from the vesting of previously granted restricted stock units.
• The sale was not an open market transaction but a share withholding transaction with the issuer.
• Following the transaction, Ms. Farnum beneficially owns 313,565 ordinary shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, which is common in publicly traded companies.

Comparison to Industry Standards

• Share sales by executives to cover tax obligations are a common practice across the pharmaceutical and biotech industries.
• These transactions are typically disclosed through SEC Form 4 filings, which is standard procedure.
• The number of shares sold and the price are within the typical range for such transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Theravance Biopharma, insider trading, stock sale, Form 4, executive compensation, tax obligations, restricted stock units